CliffBio
small molecule

ADZENYS XR-ODT

AMPHETAMINE

Loss of exclusivityJune 2032latest FDA-listed patent expiry
CompanyNEOS →View the full company profile on CliffBio

Drug detail

Brand nameADZENYS XR-ODT
Active ingredientAMPHETAMINE
StrengthEQ 18.8MG BASE
Dosage formTABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalJanuary 2016
Marketing statusRX

Listed patents

PatentExpiresType
9839619June 2032product
9017731June 2032product
9265737June 2032product
8709491June 2032product
8840924April 2026product

More from NEOS

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

ADZENYS XR-ODT patent cliff — loss of exclusivity June 2032 | CliffBio